Business Context and Reporting Period
Company: Quantum BioPharma Ltd. (formerly FSD Pharma Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Jurisdiction: Ontario, Canada (Foreign Private Issuer)
Accounting Standards: International Financial Reporting Standards (IFRS)
Quantum BioPharma is a biopharmaceutical company focused on developing drug candidates for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. The company operates through two primary segments: Biopharmaceutical (R&D of Lucid-MS and alcohol misuse treatments) and Strategic Investments (residential mortgage lending). In August 2024, the company completed a 65:1 share consolidation and changed its name and trading symbol to "QNTM."
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14,915,529) | $(18,230,588) |
| Operating Expenses | $16,136,260 | $23,789,498 |
| Cash and Cash Equivalents | $5,995,872 | $2,757,040 |
| Total Assets | $17,119,224 | $17,474,828 |
| Total Liabilities | $6,678,992 | $4,565,566 |
| Shareholders' Equity | $10,440,232 | $12,909,262 |
| Digital Assets (Crypto) | $861,230 | $0 |
Note: The company reported no revenue from product sales. Operating expenses decreased significantly in 2024 compared to 2023, primarily due to a reduction in share-based payments and the absence of impairment losses recorded in the prior year.
Material Changes vs. Prior Period
- Share Consolidation: On August 15, 2024, the company executed a 65:1 consolidation of Class A and Class B shares, reducing the share count significantly and adjusting all comparative figures retroactively.
- Cryptocurrency Treasury: The company initiated a corporate treasury strategy involving cryptocurrencies (Bitcoin, Solana, Dogecoin, XRP). As of December 31, 2024, it held digital assets with a fair value of $861,230, recognizing an unrealized loss of $141,770 for the year.
- Financing Activities: The company raised approximately $10.67 million in net proceeds through an At-The-Market (ATM) offering and issued convertible debentures totaling $702,700 in gross proceeds. It also settled significant debt obligations through the issuance of shares.
- Legal Settlements: The company secured a judgment of approximately $3 million against former CEO Dr. Raza Bokhari in the U.S. District Court for the Eastern District of Pennsylvania, though collection remains pending.
- Operational Focus: The company continued to advance the Lucid-MS program (Multiple Sclerosis) into Phase 1 Multiple Ascending Dose (MAD) trials and completed a clinical trial for its alcohol misuse product, unbuzzd™.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management anticipates continued losses for the foreseeable future as it pursues clinical development. The company estimates it requires approximately $31.5 million to advance Lucid-MS to commercialization and $11 million for its healthcare-focused alcohol misuse product. The company is actively exploring funding strategies, including equity offerings, debt financing, and potential cryptocurrency transactions.
Key Risks and Contingencies
- Clinical Development Risk: No products are currently approved for sale. Success depends on regulatory approval (FDA/Health Canada) and successful clinical trial outcomes, which are uncertain.
- Liquidity and Capital Needs: The company requires substantial additional capital to fund operations and clinical trials. Failure to secure financing could force delays or termination of programs.
- Cryptocurrency Volatility: The company's treasury strategy exposes it to significant price volatility and regulatory uncertainty regarding digital assets. As of the report date, crypto holdings represented approximately 20% of total assets.
- Legal Proceedings: Ongoing litigation includes a trade secret misappropriation claim by GBB Drink Lab (seeking ~$53 million) and a market manipulation lawsuit filed by the company against CIBC and RBC (seeking >$700 million).
- Passive Foreign Investment Company (PFIC): The company believes it was a PFIC for 2024, which may result in adverse U.S. federal income tax consequences for U.S. holders.
Investor Verification Checklist
- Cash Runway: Verify current cash balances against the estimated $31.5M+ required for Lucid-MS commercialization to assess immediate dilution risk.
- Cryptocurrency Exposure: Review the specific valuation methodology and custodial arrangements for the $861k+ in digital assets and monitor subsequent price fluctuations.
- Legal Outcomes: Monitor the status of the $3 million judgment against Dr. Bokhari (collection status) and the GBB Drink Lab litigation (potential liability).
- Share Structure: Confirm the impact of the 65:1 consolidation on voting power, noting that Class A shares (held by insiders) control approximately 59% of voting power.
- PFIC Status: Consult tax advisors regarding the implications of the company's PFIC status for U.S. investors.